<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00922324</url>
  </required_header>
  <id_info>
    <org_study_id>STP206-001</org_study_id>
    <nct_id>NCT00922324</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of STP206 in Healthy Adult Subjects</brief_title>
  <official_title>A Single-Center Randomized, Double-Blind, Placebo-Controlled Phase 1 Trial to Assess the Safety and Tolerability of Single and Multiple Daily Oral Administration of STP206 Live Biotherapeutic in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leadiant Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Leadiant Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess the safety, tolerability and fecal shedding of STP206 when given as a
      single dose and when given as daily doses for one week.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>7-days post dosing and 30-days post dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in physical examination findings</measure>
    <time_frame>7-days post dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in laboratory (hematology, chemistry, and urinalysis) variables</measure>
    <time_frame>7-days post dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fecal Shedding of STP206 components</measure>
    <time_frame>30 days post dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>STP206</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STP206 administered either as a single dose or as a daily dose for seven consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>STP206 vehicle administered as either a single dose or as a daily dose for 7 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STP206 or vehicle control</intervention_name>
    <description>STP206 or vehicle administered as either a single dose or as a daily dose for 7 consecutive days</description>
    <arm_group_label>STP206</arm_group_label>
    <arm_group_label>Vehicle Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy volunteers, 18 - 55 years of age

          2. In general good heath as established by medical history, physical examination, and
             laboratory assessment

          3. The subject is willing and able to comply with the protocol and complete all visits
             and procedures

          4. Provide written informed consent after the nature of the study has been explained

        Exclusion Criteria:

          1. Subjects with any chronic illness or conditions that require treatment

          2. Subjects with clinically significant abnormal laboratory values noted during the
             screening laboratory evaluation

          3. Subjects with history of immune compromised conditions or any past use of
             immunosuppressant treatment

          4. Subjects with current or past history of gastrointestinal disease, including any
             conditions with increased risk for bleeding (e.g., gingivitis, hemorrhoids)

          5. Subjects who are lactose intolerant

          6. Subjects who are intolerant or allergic to Splenda® or any of its ingredients
             (dextrose, maltodextrin, sucralose) or have a soy allergy

          7. Subjects who have had a fever of 100°F or higher within the 2 weeks of the first dose
             of study drug

          8. Subjects who have received a &quot;live&quot; vaccine within 30 days of the first dose of study
             drug

          9. Subjects who have received any medications (prescription or OTC) within 2 weeks of the
             first dose of study drug

         10. Subjects who have received and investigational drug with 30 days prior to the first
             dose of study drug

         11. Subjects with a history of illicit drug use or alcohol abuse

         12. Subjects with any other medical condition that may influence the objectives or
             outcomes of the study

         13. Female subjects who are pregnant or lactating

         14. Female subjects of childbearing potential who are not using an FDA approved birth
             control method

         15. Subjects who are healthcare or daycare providers or those with close contact with
             immune compromised individuals

         16. Subjects with a history of acute hepatitis, HIV infection or known to have positive
             diagnostic tests for HIV or HBV

         17. Subjects who have a planned dental appointment from screening through 7 days after
             last dose of Investigational Product.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taha Keilani, MD</last_name>
    <role>Study Director</role>
    <affiliation>Leadiant Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SNBL Clinical Pharmacology Center, Inc.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2009</study_first_submitted>
  <study_first_submitted_qc>June 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2009</study_first_posted>
  <last_update_submitted>May 16, 2013</last_update_submitted>
  <last_update_submitted_qc>May 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

